Original Article
  

Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis

Abstract

Allergen-specific immunotherapy (AIT) has confirmed its efficacy in improving the symptoms of allergic rhinitis. However, no reliable biomarkers have been identified to predict the efficacy of AIT were found. We aimed to find clinical and immunological markers to predict efficacy in children after 2 years of sublingual immunotherapy (SLIT).
A total of 285 children diagnosed with allergic rhinitis were recruited. The clinical efficacy was evaluated by comparing endpoint and baseline symptom and medication scores (SMS). Baseline clinical and immunological markers (serum total and specific immunoglobulin [Ig]E) and their correlation with clinical efficacy were analyzed.
Of the 285 children recruited, 249 completed the 2-year SLIT program. After 2 years of SLIT, 68.3% of the children showed a significant response. Children in the Remarkable Response Group had the highest baseline SMS and most extended disease duration, followed by the Effective Relief and Unresponsive Group. Correlation analysis demonstrated that SMS improvement was positively correlated with baseline SMS (r=0.67) and disease duration (r=0.35). SMS improvement was not correlated with age, body mass index, total or specific IgE levels, or their ratios.
Our results show that baseline SMS and disease duration can predict the efficacy of SLIT. Our study can guide the selection of suitable candidates for SLIT.

1. Bousquet J, Melén E, Haahtela T, Koppelman GH, Togias A, Valenta R, et al. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis. Allergy. 2023;78(5):1169-203.
2. Gradman J, Halken S. Preventive Effect of Allergen Immunotherapy on Asthma
and New Sensitizations. J Allergy Clin Immunol Pract. 2021;9(5):1813-7.
3. Penagos M, Durham SR. Allergen immunotherapy for long-term tolerance and prevention. J Allergy Clin Immunol. 2022;149(3):802-11.
4. de Blay F, Gherasim A, Casale TB, Doyen V, Bernstein D. Which patients with asthma are most likely to benefit from allergen immunotherapy? J Allergy Clin Immunol. 2022 Mar;149(3):833-43.
5. Jin Youp Kim, Myoung-Jin Jang, Dong-Young Kim, Seok-Won Park, Doo Hee Han. Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison. J Allergy Clin Immunol Pract. 2021;9(12):4450-58.e6.
6. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol. 2013;13(6):656-62.
7. Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123(5):1103-10, 10.e1-4.
8. Gupta RS, Lau CH, Hamilton RG, Donnell A, Newhall KK. Predicting outcomes of oral food challenges by using the allergen-specific IgE-total IgE ratio. J Allergy Clin Immunol Pract. 2014;2(3):300-5.
9. Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy. 2008;38(8):1290-301.
10. Pascal Demoly, Jonathan Corren, Peter Creticos, Frédéric De Blay, Philippe Gevaert, Peter Hellings, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021;147(3):1020-1030.e10.
11. Chinese Collaborative Group on Allergic Rhinitis Research. Expert Consensus on Subcutaneous Immunotherapy for Allergic Rhinitis 2015. Chinese Journal of Otolaryngology Head and Neck Surgery. 2015;22(8):379-404.
12. Li Q, Li M, Yue W, Zhou J, Li R, Lin J, et al. Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis. Int Arch Allergy Immunol. 2014;164(3):210-7.
13. Ciprandi G, Silvestri M. Serum specific IgE: a biomarker of response to allergen immunotherapy. J Investig Allergol Clin Immunol. 2014;24(1):35-9.
14. Lee JH, Kim SC, Choi H, Jung CG, Ban GY, Shin YS, et al. A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen Immunotherapy With House Dust Mites for Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10(1):18-24.
15. Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, Yasueda H, et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol. 2011;139(1):65-74.
16. Liu W, Zeng Q, Luo R. Predictors for Short-Term Efficacy of Allergen-Specific Sublingual Immunotherapy in Children with Allergic Rhinitis. Mediators Inflamm. 2020;2020:1847061.
17. Sindher SB, Long A, Acharya S, Sampath V, Nadeau KC. The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses. Clin Rev Allergy Immunol. 2018;55(2):190-204.
Files
IssueVol 23 No 1 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v23i1.14953
Keywords
Allergic rhinitis Sublingual immunotherapy
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Li Y, Xiao H, Zeng Y, Tang Y, Zhou L, Liu W. Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis. Iran J Allergy Asthma Immunol. 2024;23(1):52-58.